All In Biotech

Drug Trial Radar · NCT00153946

Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke

Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy

Last checked: Nov 20, 2026Latest source record: May 14, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

814

Actual

Start

Aug 2004

Primary completion

Mar 2008

Study completion May 2008

Sponsor

Lead sponsor
Combination Therapy for Acute Ischemic Stroke Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Japan Cardiovascular Research Foundation
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.

Conditions

  • Stroke

Interventions

  • EdaravoneDrug

    30mg/20mL vial, twice per day, not longer than two weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (MRS) scoreTime frame: at 3 months
  2. Symptomatic intracranial hemorrhageTime frame: for the initial 3 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EAST Study Office c/o National Cardiovascular Center

    Suita, Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.